ATS 2018 International Conference

Fevipiprant Efficacy in Improving Lung Function in Patients with Moderate Uncontrolled Asthma: Study Design of ZEAL 1 and ZEAL 2 Phase III Randomized Controlled Studies [Board No. P938]

Location: Board no. P938

Session Type: Thematic Poster Session

Sunday

May

11:15 AM

1:00 PM

Speaker(s)/Author(s)

Pamela Cardenas

MS
Novartis Pharmaceuticals Corporation

Vishal Mishra

MBBS
Novartis Healthcare Pvt. Ltd

David Lawrence

PhD
Novartis Pharma AG

Edward M. Kerwin

phd
Clinical Research Institute;Clinical Research Institute of Southern Oregon, PC;Crisor, LLC c/o Clinical Research Institute of Southern Oregon, Inc.

Leif Bjermer

MD, PhD
Lund University;Skåne University Hospital, Lund University

Edna Cahill

MS
Novartis Pharmaceuticals Corporation

Diego Ossa

MD
Novartis Pharma AG

Barbara A. Knorr

MD
Novartis;Novartis Pharmaceuticals Corporation

Jorge Fernando. Maspero

MD
Fundación CIDEA

View Abstract

Fevipiprant Efficacy in Improving Lung Function in Patients with Moderate Uncontrolled Asthma: Study Design of ZEAL 1 and ZEAL 2 Phase III Randomized Controlled Studies

Parent Sessions

A35 - ASTHMA CLINICAL STUDIES II
05-20-2018 9:15 AM - 4:15 PM

Event